Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHHS-2: 8-week grazoprevir + elbasvir for acute hepatitis C genotype 1/4
NL-OMON43933Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of grazoprevir and elbasvir in hepatitis C virus infection, sponsored by Erasmus MC. Primary endpoint: SVR12 in ITT population. Started Feb 2016; status: recruiting.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON43933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43933.